Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jeevan Scientific Technology Limited (JSTL.BO)
INR70.31
-0.09 (-0.13%)
IN BSE Healthcare Medical - Care Facilities
Address
Sai Krupa Enclave
Hyderabad, IN
Hyderabad, IN
CEO
Srinivas Reddy Maram
Website
jeevanscientific.com
IPO
2024-12-30
ISIN INE237B01018
Description
Jeevan Scientific Technology Ltd. functions as an outsourcing enterprise, offering global management consulting and technological solutions. The company's activities are divided into two principal divisions: Clinical Research Services and Information Technology Services. It was established on February 2, 1999, and its main corporate offices are located in Hyderabad, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR70.31
-0.09 (-0.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26.7K
Beta
0.65
Float Shares
14.93M
Free Float %
94.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.30% | +1.52% | +1.44% | +20.75% | +36.22% | +29.17% | +101.16% | +72.92% | -12.40% | +228.44% | +218.39% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
70.31
Quality scores
Altman Z-Score
3.38
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Care Facilities: +10.2%+31.4% ★ Q1'26: +111.6% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+513.2% ★ Q1'26: +212.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-17.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+5.2% Q1'26: +12.7% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+2.3% Q1'26: +9.1% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+39.8% Q1'26: +10.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×2.17× Q1'26: 1.24× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
5.15M
OE per share TTM
0.36
Owner's Yield
0.35%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
57.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.15% | 348.8K | 0.07% |
| 2 | JPMorgan BetaBuilders Emerging Markets Equity ETF BBEM | 0.12% | 970.6K | 0.15% |
| 3 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.12% | 460.0K | 0.44% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.11% | 6.15M | 0.17% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.11% | 6.15M | 0.17% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.10% | 1.40M | 0.48% |
| 7 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.10% | 3.17M | 0.26% |
| 8 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.10% | 593.0K | 0.40% |
| 9 | Vanguard FTSE Emerging Markets ETF VWO | 0.10% | 156.31M | 0.06% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.03% | 1.25M | 0.04% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
130.1K
Shares Outstanding
15.83M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Krishna Kishore Kuchipudi | Managing Director | 11M | male |
| Snigdha Mothukuri | Whole-time Director | 5M | female |
| Sharad Chandra | AVP & Head of HR | — | male |
| Srinivas Reddy Maram | Chief Executive Officer | — | — |
| Suman Avula | Head of Clinical Trials | — | — |
| Venkateswara Rao Ravipati | Chief Financial Officer | — | male |
| Vijaya Phani Kumar Chintaluri | Head of Bioanalytical Research | — | male |
| Anil Kumar Bodduluri | Head of Quality Assurance | — | — |
| Yedhupati Kondapa Naidu | Senior Vice President of Operations | — | male |
| Krishna Sainadh Kodati | Company Secretary & Compliance Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JSTL.BO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
